Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma.

Journal for immunotherapy of cancer·2024
Same author

Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance.

Blood cancer journal·2024
Same author

Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior-A case report.

EJHaem·2022
Same author

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma.

Cancers·2021
Same author

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.

Annals of hematology·2018
Same author

Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.

Hematological oncology·2015
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
查看所有相关文章

相关实验视频

Updated: Jun 22, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

多发性骨髓瘤是一种多发性骨髓瘤.

Marc S Raab1, Klaus Podar, Iris Breitkreutz

  • 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Lancet (London, England)
|June 23, 2009
PubMed
概括
此摘要是机器生成的。

多发性骨髓瘤涉及恶性血细胞和骨髓微环境. 针对两者的新疗法改善了多发性骨髓瘤和其他癌症患者的治疗结果.

更多相关视频

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

相关实验视频

Last Updated: Jun 22, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

科学领域:

  • 在瘤学瘤学.
  • 血液学 血液学 血液学

背景情况:

  • 多发性髓瘤是一种恶性血细胞的癌症.
  • 骨髓微环境在髓瘤的发展和进展中起着至关重要的作用.

研究的目的:

  • 审查骨髓微环境在多发性髓瘤发病过程中的作用.
  • 要突出针对骨髓瘤细胞及其微观环境的新型治疗剂的影响.

主要方法:

  • 对多发性骨髓瘤及其治疗现有文献的综述.
  • 对thalidomide, bortezomib和lenalidomide等药物的作用机制的分析.

主要成果:

  • 针对骨髓微环境与髓瘤细胞一起,提高了治疗效率.
  • 像thalidomide, bortezomib和lenalidomide这样的药物已经显示出显著的益处.
  • 这些药物改善了整体反应,反应持续时间,无进展生存率和整体生存率.

结论:

  • 骨髓微环境是多发性骨髓瘤的关键治疗点.
  • 将这些新型药物纳入一线治疗方案为患者提供了更好的结果.
  • 这种治疗方法对其他血液性恶性瘤和固体瘤也具有前景.